In a September 2013 JAMA Internal Medicine article, Health Care–Associated Infections: A Meta-analysis of Costs and Financial Impact on the US Health Care System, the authors provide estimates of the costs associated with what they termed “significant and targetable” healthcare …
MRSA and C. difficile vaccination: “An ounce of prevention worth a pound of cure”? Read More »
Great news needs to be shared! It is so nice to see such dramatic and positive benefits from a treatment. The beauty of vaccines lies in their typical cost-effective and dramatic efficacy. In the June 19, 2013 Journal of Infectious …
Biogen Idec’s Tecfidera (dimethyl fumarate) has been approved by the FDA for the treatment of people with relapsing forms of multiple sclerosis (MS). The wholesale acquisition price for Tecfidera is reported to be $54,900, about 9% less than the first MS …
